BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vidofludimus: Final Phase IIb data

Final data from the double-blind, placebo-controlled, European Phase IIb COMPONENT trial in 236 patients showed that once-daily 35 mg oral vidofludimus plus methotrexate reduced C-reactive protein (CRP) levels from baseline to week 13 by 1.82 mg/L vs. an increase of 1.38 mg/L for methotrexate alone. Vidofludimus plus methotrexate also reduced erythrocyte sedimentation rate (ESR)...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >